Home › Research › Biomarkers
Label-free detection of β-amyloid peptides (Aβ40 and Aβ42): a colorimetric sensor array for plasma monitoring of Alzheimer's disease
Ghasemi F, Hormozi-Nezhad MR, Mahmoudi M.. Nanoscale, 2018-04-01
Topic: Plasma and spinal-fluid biomarkers
Plain-language summary
Monitoring the ratio of 40- and 42-residue amyloid β peptides (i.e., Aβ40 and Aβ42) in human plasma is considered one of the hallmarks of detection of the early stage of Alzheimer's disease (AD). Therefore, development of a specific, yet non-antibody-based method for simultaneous detection of Aβ40 and Aβ42 may have considerable clinical applications. Here, we developed a 'nanoparticle-based colorimetric sensor array' utilizing label-free gold and silver nanoparticles for visual detection of Aβ42 and Aβ40. Different aggregation behaviors of nanoparticles through their conjugation with Aβ42 and Aβ40 followed by the coordination of Aβ42 and Aβ40 with Cu(ii) led to diverse spectral and color changes. The spectral changes were quantitatively differentiated by a supervised pattern recognition approach, linear discriminant analysis (LDA). The proposed sensor array was able to discriminate among Aβ42, Aβ40, and HSA in different concentrations (50 nmol L-1 to 500 nmol L-1) and their mixtures. Moreover, the sensor array had the capability to identify structurally similar Aβ peptides in human plasma samples. The developed sensor array technology might pave the way for a cheap and rapid, yet robust, platform for high-throughput screening of human plasma for defining the at-risk population for AD.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Ghasemi, F., Hormozi-Nezhad, M. R., & Mahmoudi, M. (2018). Label-free detection of β-amyloid peptides (Aβ40 and Aβ42): a colorimetric sensor array for plasma monitoring of Alzheimer's disease. Nanoscale. https://doi.org/10.1039/c8nr00195b
Vancouver
Ghasemi F, Hormozi-Nezhad MR, Mahmoudi M. Label-free detection of β-amyloid peptides (Aβ40 and Aβ42): a colorimetric sensor array for plasma monitoring of Alzheimer's disease. Nanoscale. 2018. doi:10.1039/c8nr00195b. PMID: 29561053.
BibTeX
@article{ghasemi2018-29561053,
author = {Ghasemi, F. and Hormozi-Nezhad, M. R. and Mahmoudi, M.},
title = {{Label-free detection of β-amyloid peptides (Aβ40 and Aβ42): a colorimetric sensor array for plasma monitoring of Alzheimer's disease}},
journal = {Nanoscale},
year = {2018},
doi = {10.1039/c8nr00195b},
pmid = {29561053},
url = {https://doi.org/10.1039/c8nr00195b}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Different aggregation behaviors of nanoparticles through their conjugation with Aβ42 and Aβ40 followed by the coordination of Aβ42 and Aβ40 with Cu(ii) led to diverse spectral and color changes.
- The spectral changes were quantitatively differentiated by a supervised pattern recognition approach, linear discriminant analysis (LDA).
- The proposed sensor array was able to discriminate among Aβ42, Aβ40, and HSA in different concentrations (50 nmol L-1 to 500 nmol L-1) and their mixtures.
- Moreover, the sensor array had the capability to identify structurally similar Aβ peptides in human plasma samples.
- The developed sensor array technology might pave the way for a cheap and rapid, yet robust, platform for high-throughput screening of human plasma for defining the at-risk population for AD.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Evidence strengthLow
How this study scored 38/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 22 of the 58 points we could judge it on, which is 38 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Nanoscale) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2018 — within 10 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 29561053) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 22 / 58 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 22 of the 58 points we could judge it on is 38 out of 100. |
| Total | 38 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Biomarkers from nearby years
Also tagged “p-tau217”
693 studies in the library carry the topic tag “p-tau217”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 693 tagged studies.